Provenge
(Sipuleucel-T)Phase 3Cell therapy
Sipuleucel-T is used to treat advanced prostate cancer in men whose cancer no longer responds to hormone therapy. It works by boosting the patient's own immune system to fight the cancer cells.[1] Provenge is currently being investigated across 5 indications[3], with its most advanced program in Phase 3.[1]
Provenge is one of 157 small molecule programs targeting Prostate Adenocarcinoma. It is currently in Phase 3.
5
Indications
32
Total Trials
5
Active Trials
156
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1399 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Provenge
PProstate Oncology Specialists, Inc.
Phase 3
Novantrone
PfizerPreclinical
Mekinist
NovartisPreclinical
Trexall
Alnylam PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Ranexa
MMenarini International Operations Luxembourg SA
Preclinical
Duragesic
CCephalon
Preclinical
Viagra
VViatris Specialty LLC
Preclinical
Prednisone/prednisolone
RochePreclinical
Triptorelin Pamoate
IpsenPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer20 trials
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Recruiting·—·Phase 1·NCT07219147·30 enrolled
Show 17 more trials
Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer
Completed·—·Phase 1·NCT02036918·20 enrolled
Metastatic Prostate Cancer7 trials
Show 4 more trials
Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Completed·—·Phase 2·NCT01807065·51 enrolled
mCRPC1 trial
Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02463799·36 enrolled
Concentration1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sipuleucel-T. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details